Want to see HK:2325 full AI Analyst Report?
Yunkang Group Limited (2325) AI Stock Analysis
Yunkang Group Limited
(HKEX:2325)
The score is driven primarily by a mixed financial profile: strong and improving free cash flow and a 2025 operating rebound support the outlook, but multi-year revenue decline and unstable profitability (only modest net profit in 2025) materially reduce quality and visibility. Technically, momentum is positive but overbought signals raise pullback risk. A low P/E provides valuation support.
Yunkang Group Limited (2325) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 362.91M
- Dividend Yield
- ―
- Average Volume (3M)
- 288.01K
- Price to Earnings (P/E)
- 5.3
- Beta (1Y)
- 0.01
- Revenue Growth
- -13.34%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 1,064
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Yunkang Group Limited Business Overview & Revenue Model
Company Description
Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical in...
Yunkang Group Limited Financial Statement Overview
Summary
Fundamentals are mixed. Positives include strong and improving cash generation (2025 operating cash flow ~302M; free cash flow ~246M, +52% YoY) and a 2025 operating rebound (EBIT margin ~15%). Offsetting this are a steep multi-year revenue contraction (2023: -76%, 2024: -0.2%, 2025: -9.2%) and highly volatile profitability with only marginal net profitability in 2025 (~0.5% net margin). Leverage is moderate but higher than earlier years (debt/equity ~0.60 in 2025).
Income Statement
44NeutralBalance Sheet
53NeutralCash Flow
69Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 540.93M | 601.39M | 711.88M | 891.50M | 3.76B | 1.70B |
| Gross Profit | 154.65M | 182.82M | 211.07M | 325.79M | 1.47B | 1.07B |
| EBITDA | 146.49M | 133.41M | -668.52M | 25.07M | 596.45M | 512.57M |
| Net Income | 60.70M | 2.92M | -791.68M | -102.26M | 377.31M | 380.93M |
Balance Sheet | ||||||
| Total Assets | 2.69B | 2.74B | 3.23B | 4.53B | 5.51B | 3.00B |
| Cash, Cash Equivalents and Short-Term Investments | 1.64B | 1.77B | 1.73B | 1.87B | 1.43B | 800.70M |
| Total Debt | 688.17M | 692.60M | 1.07B | 1.39B | 786.12M | 362.02M |
| Total Liabilities | 1.53B | 1.57B | 2.08B | 2.41B | 2.66B | 1.23B |
| Stockholders Equity | 1.16B | 1.16B | 1.14B | 2.33B | 2.84B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 246.23M | 228.38M | 271.63M | -239.05M | 141.06M |
| Operating Cash Flow | 0 | 301.61M | 258.84M | 333.84M | 130.33M | 413.26M |
| Investing Cash Flow | 0 | 313.56M | 354.02M | -153.94M | -1.25B | 310.72M |
| Financing Cash Flow | 0 | -414.36M | -535.63M | 276.48M | 1.10B | -215.32M |
Yunkang Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2325, the sentiment is Positive. The current price of 0.62 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.53, and below the 200-day MA of 0.71, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 70.06 is Negative, neither overbought nor oversold. The STOCH value of 64.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2325.
Yunkang Group Limited Peers Comparison
Overall Rating
- HK:232561Neutral
HK:215956Neutral
HK:386954Neutral
HK:213841Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2325 | 61Neutral | HKD 385.18M | 5.31 | 5.25% | ― | -13.34% | ― |
| HK:2159 | 56Neutral | HKD 528.27M | 9.63 | 28.00% | ― | 91.32% | ― |
| HK:3869 | 54Neutral | HKD 467.79M | -143.62 | -0.41% | ― | 3.16% | -101.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2138 | 41Neutral | HKD 645.94M | -1.61 | -25.36% | ― | -8.94% | -140.82% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2325 | Yunkang Group Limited | 0.62 | -0.38 | -38.00% | |
| HK:2138 | EC Healthcare | 0.55 | -0.10 | -16.15% | |
| HK:2159 | Mediwelcome Healthcare Management & Technology Inc. | 1.57 | 0.40 | 34.19% | |
| HK:2279 | Yonghe Medical Group Co., Ltd. | 2.10 | 0.20 | 10.55% | |
| HK:3869 | Hospital Corporation of China Ltd | 3.38 | -2.61 | -43.49% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% |
Yunkang Group Limited Corporate Events
Yunkang Swings to Profit Despite Revenue Drop on Cost Cuts and Efficiency Gains
Yunkang Group Limited, a healthcare diagnostics service provider focused on medical institution alliances, diagnostic outsourcing, and non-medical testing services in China, continues to refine its customer mix and product portfolio to strengthen its...
Yunkang Group Sets August Board Meeting to Review Interim Results and Dividend
Yunkang Group Limited has scheduled a board meeting for August 28, 2026 to approve its interim results for the six months ended June 30, 2026 and to authorize their publication. The directors will also consider the declaration of an interim dividend,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026